1887

n South African Medical Journal - Clinical Access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis : forum - clinical practice

USD

 

Abstract

While clinical disease caused by drug-sensitive (MTB) can usually be treated successfully, clinical disease caused by drug-insensitive MTB is associated with a poorer prognosis. In December 2012, a new drug, bedaquiline, was approved by the US Food and Drug Administration. This article documents the process whereby the National Department of Health, Right to Care and Médecins Sans Frontières obtained access to this medication for South Africans who might benefit from subsequent implementation of the Clinical Access to Bedaquiline Programme.

Loading

Article metrics loading...

/content/m_samj/104/3/EJC149647
2014-03-01
2016-12-04
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error